Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study

BACKGROUND/AIMS: The efficacy and safety of vedolizumab in moderate-to-severely active Crohn’s disease (CD) were demonstrated in the GEMINI 2 study (NCT00783692). This post-hoc exploratory analysis aimed to assess the efficacy and safety of vedolizumab in the subgroup of patients from Asian countrie...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Intest Res
Huvudupphovsmän: Banerjee, Rupa, Chuah, Sai Wei, Hilmi, Ida Normiha, Wu, Deng-Chyang, Yang, Suk-Kyun, Demuth, Dirk, Lindner, Dirk, Adsul, Shashi
Materialtyp: Artigo
Språk:Inglês
Publicerad: Korean Association for the Study of Intestinal Diseases 2021
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7873405/
https://ncbi.nlm.nih.gov/pubmed/33378612
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2019.09160
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk